Sagimet Biosciences Inc. SEC filings SGMT

Sagimet Biosciences Inc. has 262 filings in SEC EDGAR's recent list, going back to May 8, 2007. Its latest annual report, Form ARS, was filed on Apr 21, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 22, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.

Sagimet Biosciences Inc. SEC filings
Form Description Filed Period
424B5 Prospectus supplement Oct 1, 2026 —
424B3 Prospectus Sep 30, 2026 —
424B5 Prospectus supplement Apr 28, 2026 —
S-8 Employee stock plan registration Mar 11, 2026 —
S-8 Employee stock plan registration Mar 11, 2026 —
424B5 Prospectus supplement Aug 14, 2025 —
S-8 Employee stock plan registration Mar 12, 2025 —
S-8 Employee stock plan registration Mar 12, 2025 —
S-3 Shelf registration Aug 15, 2024 —
S-8 Employee stock plan registration Mar 25, 2024 —
424B4 Prospectus Jan 29, 2024 —
S-1/A Amended registration statement Jan 24, 2024 —
S-1 Registration statement Jan 23, 2024 —
S-8 Employee stock plan registration Jul 17, 2023 —
424B4 Prospectus Jul 17, 2023 —
S-1MEF Filing Jul 13, 2023 —
S-1/A Amended registration statement Jul 10, 2023 —
S-1/A Amended registration statement Jul 3, 2023 —
S-1 Registration statement Jun 23, 2023 —
S-1/A Amended registration statement May 10, 2021 —
S-1 Registration statement Apr 16, 2021 —

Showing 21 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
SGMT (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Foster City, CA
SEC filer status
, Emerging growth company
SEC CIK
1400118
Former names
3-V Biosciences, Inc. (until Feb 25, 2019)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.